<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556594</url>
  </required_header>
  <id_info>
    <org_study_id>16416</org_study_id>
    <secondary_id>I8R-MC-IGBA</secondary_id>
    <secondary_id>AMG102</secondary_id>
    <nct_id>NCT01556594</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia</brief_title>
  <acronym>AMG102</acronym>
  <official_title>Phase II Study to Investigate the Safety and Efficacy of 2 Dose Levels of a Novel Glucagon Formulation Compared to Commercially Available Glucagon in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoglycemia is common in people with type 1 diabetes. Mild and moderate hypoglycaemia is
      normally treated by consuming oral carbohydrates. During an episode of severe hypoglycaemia
      however, the person with diabetes is unable to consume carbohydrates and requires help from
      another person. The current standard treatment for severe hypoglycemia is intravenous glucose
      or an injection of glucagon, which causes an increase of blood glucose, which allows the
      person with diabetes to recover sufficiently to consume carbohydrate.

      AMG Medical is investigating a novel formulation of glucagon which may be easier to
      administer than the currently available glucagon formulations.

      In this study, patients with Type 1 diabetes will receive injected insulin to reduce their
      blood glucose, and will then receive one of three doses of the new glucagon formulation or a
      dose of glucagon for injection, and their blood glucose will be measured for 3 hours.

      The study hypothesis is that the new glucagon formulation will be as effective as the current
      injected formulation at raising blood glucose levels within 15 minutes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On each study day patients will be admitted to the clinical site at least 10 hours prior to
      glucagon administration.

      Each patient will be weighed in a hospital gown in the evening prior to glucagon
      administration to adjust the insulin infusion rate individually.

      Blood glucose values will be measured using a bedside rapid glucose analyzer. Blood glucose
      levels will be controlled overnight prior to dosing.

      On the morning of dosing after a supervised overnight fast, hypoglycemia will be induced by
      IV insulin infusion prior to dosing. Glucose levels will be measured throughout the IV
      insulin infusion process and once a value of ≤3.6 mmol/L is observed, the insulin infusion
      will be stopped and within 5 minutes, subjects will be treated with one of the four
      treatments.

      Serial blood sampling for PK (glucagon) and PD (glucose) assessments will be performed before
      and after glucagon administration.

      In addition to the blood sampling schedule for glucose PD measurement, glucose levels will
      also be measured regularly throughout the procedure with a beside glucose analyzer for safety
      monitoring of patients. Minimally, measurements will be performed at each PK/PD blood draw.

      For each study period administration sites will be closely evaluated for tolerability.

      Before departure about 6 hours after glucagon administration, the glucose and insulin dosing
      and their stabilization will be evaluated by the physician to ensure the safety of the
      patient.

      These procedures will be applied for each period of the study.

      Drug Administration Procedure

      In each study period, a single dose of glucagon will be administered in the morning after a
      10-hour overnight fast and following insulin-induced hypoglycemia, using either the new
      glucagon formulation or glucagon for injection.

      Treatments 1 and 2 and 3 - New formulation:

      Treatment 4 - Subcutaneous administration:

      The approved dose level of 1 mg of glucagon will be injected under the skin

      A nurse will be at the clinical site overnight before glucagon administration to ensure
      safety of the patients. In addition, the physician in charge will remain at the clinical site
      from the start of the insulin infusion in the morning until at least the first 6 hours
      following each glucagon administration to ensure patients are re-stabilized in their regular
      insulin medication before departure. The physician in charge will also remain available at
      all times during the entire period of the study.

      End of the study The following post-study tests will be performed after the collection of the
      last blood sample of the study.

        -  Physical examination

        -  Laboratory tests

        -  Biochemistry

        -  Hematology

        -  Urinalysis

        -  HCG beta serum pregnancy test (female patients).

        -  12-lead ECG
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders</measure>
    <time_frame>Within 30 minutes of treatment with test article</time_frame>
    <description>A responder will be defined as a subject who achieved normal blood glucose ( ≥3.8 mmol/L) within 30 minutes after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With at Least One Adverse Event</measure>
    <time_frame>Safety evaluations were recorded from dosing up until 3 hours after dosing with test medication</time_frame>
    <description>Safety and tolerability will be evaluated through the assessment of adverse events, physical examination, laboratory tests, vital signs and ECG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Peak Plasma Concentration (Cmax) of Glucose</measure>
    <time_frame>Samples were obtained at 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
    <description>mean plasma glucose level after treatment with test article</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>SC glucagon injection 1 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose novel formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose novel formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose novel formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose novel formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose novel formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose novel formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucagon</intervention_name>
    <description>glucagon solution for injection containing 1 mg of glucagon Single subcutaneous injection</description>
    <arm_group_label>SC glucagon injection 1 mg</arm_group_label>
    <other_name>Glucagon for injection (rDNA origin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose novel formulation</intervention_name>
    <description>Low dose novel formulation</description>
    <arm_group_label>Low dose novel formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose novel formulation</intervention_name>
    <description>high dose novel formulation</description>
    <arm_group_label>High dose novel formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medium dose novel formulation</intervention_name>
    <description>Medium dose novel formulation</description>
    <arm_group_label>Medium dose novel formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of type 1 diabetes between 2 and 30 years

          -  Receiving daily insulin injections or insulin pump therapy for at least 2 years

          -  If patient is taking Lantus, Levemir or equivalent once-daily in the evening as basal
             insulin, must be willing to transition to once-daily in the morning at least 48 hours
             prior to 1st dosing, and to follow this dosing regimen for the entire duration of the
             study

          -  Body mass index (BMI) greater than or equal to 20.00 and below or equal to 33.00 kg/m2

          -  Female patients must not be pregnant, and must be using effective contraception.

          -  Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes
             or less per day for at least 3 months before day 1 of this study. An ex smoker is
             defined as someone who completely stopped smoking for at least 6 months before day 1
             of this study

        Exclusion Criteria:

          -  History of an episode of severe hypoglycemia (as defined by an episode that required
             third party assistance for treatment) in the previous 6 months before day 1 of this
             study

          -  Score ≥4 on the Clarke Hypoglycemia Awareness survey at screening

          -  Presence or history of pheochromocytoma (i.e. adrenal gland tumor)

          -  Presence or history of significant upper respiratory or allergic (i.e., seasonal
             rhinitis) disease

          -  Presence of clinically significant findings on nasal examination and bilateral
             anterior rhinoscopy

          -  Known presence of hereditary problems of galactose and /or lactose intolerance

          -  History of significant hypersensitivity to glucagon or any related products as well as
             severe hypersensitivity reactions (like angioedema) to any drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <results_first_submitted>March 18, 2013</results_first_submitted>
  <results_first_submitted_qc>August 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2014</results_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglycemia</keyword>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the clinical site's database and from patients who responded to advertising in local media.</recruitment_details>
      <pre_assignment_details>No significant events occurred with respect to any of the subjects following enrolment. All participants recruited to participate in the study completed all arms of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gp 1: Low Dose IN, Med Dose IN, SC</title>
          <description>Low dose IN followed by med dose IN followed by SC injection of glucagon</description>
        </group>
        <group group_id="P2">
          <title>Gp 2: Low Dose IN, Med Dose IN, SC, High Dose IN</title>
          <description>Low dose IN followed by medium dose IN followed by SC followed by high dose IN glucagon</description>
        </group>
        <group group_id="P3">
          <title>Gp 3: Med Dose IN, SC, High Dose IN</title>
          <description>Med dose IN followed by SC followed by high dose IN glucagon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy volunteers</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Low dose IN followed by med dose IN followed by SC injection of glucagon</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Low dose IN followed by med dose IN followed by SC injection followed by high dose IN of glucagon</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Med dose IN followed by SC injection followed by high dose IN of glucagon</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="14"/>
                    <measurement group_id="B2" value="42" spread="2"/>
                    <measurement group_id="B3" value="25" spread="6"/>
                    <measurement group_id="B4" value="32" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Responders</title>
        <description>A responder will be defined as a subject who achieved normal blood glucose ( ≥3.8 mmol/L) within 30 minutes after treatment.</description>
        <time_frame>Within 30 minutes of treatment with test article</time_frame>
        <population>All subjects were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon Injection</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Novel Form'n</title>
            <description>Low dose novel formulation</description>
          </group>
          <group group_id="O3">
            <title>High Dose Novel Form'n</title>
            <description>High dose novel formulation</description>
          </group>
          <group group_id="O4">
            <title>Medium Dose Novel Form'n</title>
            <description>Medium dose novel formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders</title>
          <description>A responder will be defined as a subject who achieved normal blood glucose ( ≥3.8 mmol/L) within 30 minutes after treatment.</description>
          <population>All subjects were included in the analysis</population>
          <units>percentage of patients treated</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With at Least One Adverse Event</title>
        <description>Safety and tolerability will be evaluated through the assessment of adverse events, physical examination, laboratory tests, vital signs and ECG.</description>
        <time_frame>Safety evaluations were recorded from dosing up until 3 hours after dosing with test medication</time_frame>
        <population>All patients who were treated were included in the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon Injection</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Novel Form'n</title>
            <description>Low dose novel formulation</description>
          </group>
          <group group_id="O3">
            <title>High Dose Novel Form'n</title>
            <description>high dose novel formulation</description>
          </group>
          <group group_id="O4">
            <title>Medium Dose Novel Form'n</title>
            <description>Medium dose novel formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With at Least One Adverse Event</title>
          <description>Safety and tolerability will be evaluated through the assessment of adverse events, physical examination, laboratory tests, vital signs and ECG.</description>
          <population>All patients who were treated were included in the analysis</population>
          <units>participants with at least one AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Peak Plasma Concentration (Cmax) of Glucose</title>
        <description>mean plasma glucose level after treatment with test article</description>
        <time_frame>Samples were obtained at 0.08, 0.17, 0.25, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 2.5 and 3.0 hours after glucagon administration</time_frame>
        <population>All subjects treated were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>SC Glucagon Injection</title>
            <description>SC glucagon injection 1 mg</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Novel Form'n</title>
            <description>Low dose novel formulation</description>
          </group>
          <group group_id="O3">
            <title>High Dose Novel Form'n</title>
            <description>High dose novel formulation</description>
          </group>
          <group group_id="O4">
            <title>Medium Dose Novel Form'n</title>
            <description>Medium dose novel formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Peak Plasma Concentration (Cmax) of Glucose</title>
          <description>mean plasma glucose level after treatment with test article</description>
          <population>All subjects treated were analyzed</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="0.8"/>
                    <measurement group_id="O2" value="8.03" spread="0.7"/>
                    <measurement group_id="O3" value="8.5" spread="0.8"/>
                    <measurement group_id="O4" value="8.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SC Glucagon Injection</title>
          <description>SC glucagon injection 1 mg</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Novel Form'n</title>
          <description>Low dose novel formulation</description>
        </group>
        <group group_id="E3">
          <title>High Dose Novel Form'n</title>
          <description>high dose novel formulation</description>
        </group>
        <group group_id="E4">
          <title>Medium Dose Novel Form'n</title>
          <description>Medium dose novel formulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Lacrimation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MeDRA 10.0">Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title vocab="MeDRA 10.0">Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 13.0">Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 13.0">Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 13.0">Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 13.0">Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 13.0">Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 13.0">Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

